Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
94 hedge funds and large institutions have $133M invested in Paratek Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 16 closing their positions.
339% more call options, than puts
Call options by funds: $720K | Put options by funds: $164K
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
8% more capital invested
Capital invested by funds: $124M → $133M (+$9.33M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less funds holding
Funds holding: 102 → 94 (-8)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.13M |
| 2 |
Millennium Management
New York
|
+$1.35M |
| 3 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$1.34M |
| 4 |
AC
Armistice Capital
New York
|
+$1.01M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$587K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$702K |
| 2 |
BlackRock
New York
|
-$445K |
| 3 |
Two Sigma Investments
New York
|
-$390K |
| 4 |
Renaissance Technologies
New York
|
-$377K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$348K |
PRTK Hedge Fund Activity: Q1 2019 in Review
94 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2019, worth a combined $133M — up 7.5% from $124M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PRTK and 8 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 33 added.
The largest buyer was Vanguard Group, adding an estimated $3.13M. The largest seller was Baird Financial Group, cutting an estimated $702K.
- 94 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2019, down from 102 in Q4 2018.
- Funds reported $133M of Paratek Pharmaceuticals, Inc. stock for Q1 2019, up 7.5% quarter-over-quarter.
- 8 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2019 and 16 closed out, a net change of -8 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2019 was Vanguard Group, an estimated $3.13M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2019 was Baird Financial Group, an estimated $702K sold.
Based on aggregated 13F filings for Q1 2019.